TITLE:
Trimetazidine and Cellular Response in Cardiopulmonary Bypass*
AUTHORS:
Gerez Fernandes Martins, Aristarco G. de Siqueira Filho, João Bosco de F. Santos, Claudio Roberto Cavalcanti Assunção, Alberto Valência, Gerez Martins
KEYWORDS:
Trimetazidine; Administration and Dosage; Myocardial Reperfusion; Inflammation; Cellular Re-sponse; Myocardial Revascularization
JOURNAL NAME:
World Journal of Cardiovascular Surgery,
Vol.3 No.5,
September
23,
2013
ABSTRACT: Background: Organic cellular inflammatory response constitutes a pathophysiological mechanism present in all Coronary Artery Bypass Graftings (CABGs). In this aspect, the organism brings forth its defenses through answers that involve cellular components. Objectives: To evaluate, in a randomized double-blind prospective study, controlled with placebo, the effects of trimetazidine (Tmz) on cellular response, analyzed through the variation of leukocytes, neutrophils and monocytes. Patients and Method: 30 patients were randomly selected to be studied, with no more than a mild ventricular dysfunction, and divided into two groups (Tmz and placebo) stratified by echocardiography and receiving medication/placebo in a 60 mg/day dose. The samples of leukocytes, neutrophils and monocytes were obtained in the pre-operatory day without medication, at surgery day with 12 to 15 days of medication/placebo, with 5 minutes after the aortic declamping, and within 12, 24 and 48 hours after surgery. Results: The leukocytes and neutrophils levels have decreased significantly in the treated group when compared to the control group, in all analyzed moments (p = 0.012; p = 0.005). Conclusions and Clinical Implications: Trimetazidine has proved to reduce significantly the levels of total leukocytes and neutrophils in patients submitted to CABG.